• VIBHA RANI Department of Pharmacology, Malla Reddy Medical College for Women, Suraram, Hyderabad, India.
  • SAILAXMI VENEPALLY Department of Pharmacology, Pratima Institute of Medical Sciences, Karimnagar, Telangana, India.


Objectives: The objectives of the study are to evaluate the cost variation and cost ratio of different brands of the drugs used in the treatment of benign prostatic hyperplasia (BPH).

Methods: The cost of alpha-blockers and 5 alpha-reductase inhibitors used in the treatment of BPH was noted from CIMS (Oct 2019–Jan 2020), Drugs Update, and Medline. The differences between the maximum and minimum cost of various brands of the same drug were analyzed and percentage variation in the cost was calculated. The results of the study were expressed in absolute numbers and percentages.

Results: All the drugs used in the treatment of BPH are only available in tablet and capsule forms, in 10 different dosages and in 242 different brand names, of which 10 mg alfuzosin and 2.5 mg finasteride have the highest (518) and lowest (14) percentage of cost variation, while 0.4 mg tablet form of tamsulosin is available in the maximum number of brands-41.

Conclusion: This pharmacoeconomic study reveals that there is wide variation in the cost of most of the drugs used in the treatment of BPH. Therefore, it is very much essential for both government and pharmaceutical companies to make combined efforts to reduce the cost of these drugs, which will reduce the economic burden on the patients and also reduce the overall health care costs.

Keywords: Benign prostatic hyperplasia, Cost variation, Cost ratio, Drugs, Pharmacoeconomics


1. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol 2012;19:10-7.
2. Praveen R. Benign prostatic hyperplasia: An updated review. Int Res J Pharm 2013;4:45-51.
3. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol 2014;30:170-6.
4. Madersbacher S, Sampson N, Culig N. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology 2019;65:458-64.
5. Anwar AR, Basha AA. Benign prostatic hyperplasia and its association with ABO blood group system. J Med Sci Clin Res 2015;3:6095-9.
6. De la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001;40:256-63.
7. Andrade C, Rao TS. Prescription writing: Generic or brand? Indian J Psychiatry 2017;59:133-7.
8. Narula S. Current drug pricing status in India. Pharmacoeconomics 2015;1:e101.
9. Atal S, Atal S, Deshmankar B, Nawaz SA. Cost analysis of commonly used drugs under price control in India: Assessing the effect of drug price control order on brand price variation. Int J Pharm Pharm Sci 2016;8:315-21.
10. Kamath L, Satish GR. Cost variation analysis of antihypertensive drugs available in Indian market: An economic perspective. Int J Pharm Sci Res 2016;7:2050-6.
11. Chawan VS, Badwane SV, Gawand KV, Chhaya MU. Analysis of price variation amongst different formulations of anxiolytic drugs available in Indian market. Int J Res Med Sci 2016;4:2398-401.
12. Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders. Cureus 2020;12:e7964.
13. Kolasani BP, Malathi DC, Ponnaluri RR. Variation of cost among anti-cancer drugs available in Indian market. J Clin Diagn Res 2016;10:FC17-20.
14. Bhaskarabhatla A, Chatterjee C, Anurag P, Pennings E. Mitigating regulatory impact: The case of partial price controls on metformin in India. Health Policy Plan 2017;32:194-4.
15. Mir SA. Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: A pharmacoeconomic study. Int J Basic Clin Pharmacol 2018;7:556-60.
16. Cyril JK. Pharmacy pricing and out-of-pocket health care expenditure in India. Biomed J Sci Tech Res 2018;6:1-2.
17. Angell BJ, Prinja S, Gupt A, Jha V, Jan S. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana and the path to universal health coverage in India: Overcoming the challenges of stewardship and governance. PLoS Med 2019;16:e1002759.
18. Chikkamath V, Nagappa AN. Pradhan Mantari Jan Aushadi Kendra-demonetarization of medicine prices in India. J Gen Pract 2016;4:1-5.
19. Undergraduate Curriculum-Volume 1 by Medical Council of India. Available from: https://www.nmc.org.in/wp-content/uploads/2020/01/ UG-curriculum-Vol-I.pdf. [Last assessed on 2021 Feb 13].
20. Roy V, Rana P. Prescribing generics: All in a name. Indian J Med Res 2018;147:442-4.
21. Panayappan L, Jose JM, Joseph JG, Jayapal K, Saju S, Kumar KK. Prescription audit and prescribing indicators: A review. J Bio Innov 2017;6:542-7.
9 Views | 10 Downloads
How to Cite
RANI, V., and S. VENEPALLY. “A COST VARIATION ANALYSIS STUDY OF DRUGS USED IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA AVAILABLE IN THE INDIAN MARKET”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 6, May 2021, pp. 152-5, doi:10.22159/ajpcr.2021.v14i6.41291.
Original Article(s)